Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Aplastic anemia not responsive to immunosuppressive therapy Metastatic renal cell carcinoma Hematologic malignancy, including any of the following: Acute myeloid leukemia (AML)* not curable with chemotherapy and meeting any of the following criteria: AML with high-risk cytogenetic abnormalities (e.g., -7, -7q, -5, -5q, complex, Philadelphia chromosome-positive [Ph+]) AML evolved from prior myelodysplasia AML secondary to prior chemotherapy Failed to achieve remission In second or subsequent remission NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy Myelodysplasia* with any of the following high-risk features: Adverse cytogenetics (-7, 7q, -5, -5q, complex) Excess blasts Prior conversion to AML Severe cytopenias with absolute neutrophil count < 500/mm^3 or platelet count < 20,000/mm^3 NOTE: *Marrow blasts < 10%- can be achieved by chemotherapy Acute lymphoblastic leukemia (ALL)* not curable with chemotherapy and meeting any of the following criteria: High-risk cytogenetics (Ph+, 11q23 abnormalities, monosomy 7) More than 1 induction course required to achieve remission Failed to enter remission In second or subsequent remission NOTE: *Marrow blasts < 10 % Chronic lymphocytic leukemia (CLL) with high-risk features, including any of the following: Refractory to initial or subsequent therapy Progression after initial response to therapy Prolymphocytic morphology Follicular lymphoma with any of the following high-risk features: Refractory to initial or subsequent therapy Progression after response to initial therapy Has ≥ 3 International Prognostic Index (IPI) risk factors Multiple myeloma Stage II-III disease confirmed at diagnosis or after initial progression Other lymphoma that has failed to respond to primary therapy, progressed, or recurred after prior therapy, including any of the following: Diffuse large cell lymphoma Mantle cell lymphoma Hodgkin's lymphoma Myeloproliferative disease with evidence of disease acceleration, including any of the following: Myelofibrosis Polycythemia vera Essential thrombocythemia Chronic myeloid leukemia (CML) that failed to be controlled by imatinib mesylate Disease must be stable or responding to therapy No rapid progression of malignant disease Expected time to disease progression > 12 weeks Not eligible for autologous stem cell transplantation Matched unrelated donor available 9/10 HLA matched, including HLA-A, -B, -C, -DR, and -DQ PATIENT CHARACTERISTICS: Creatinine < 2.0 mg/dL Creatinine clearance > 40 mL/min Bilirubin < 3 mg/dL Elevated total bilirubin due to Gilbert's disease allowed if direct bilirubin is normal AST < 4 times upper limit of normal Hepatitis C or B allowed provided bilirubin and AST are normal Cardiac ejection fraction > 30% DLCO > 40% of predicted Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled active infection requiring ongoing antibiotic treatment No poor performance status No poor organ function PRIOR CONCURRENT THERAPY: See Disease Characteristics Prior stem cell or bone marrow transplantation allowed